Table 2.

PSA results after an elevation greater than or equal to 2.5 ng/mL. Elevated denotes PSA ≥ 2.5 ng/mL, not elevated PSA < 2.5 ng/mL; Entries in table are number (%) of incidences.

	No biopsy	One or more negative biopsies	Prostate cancer case
Next consecutive PSA following an elevated PSA*
Not elevated	173 (23.3%)	61 (17.3%)	6 (8.8%)
Elevated	571 (76.7%)	292 (82.7%)	62 (91.2%)
Next 2 consecutive PSAs following an elevated PSA**
Both not elevated	90 (19.5%)	29 (11.1%)	0 (0.0%)
Both elevated	312 (67.5%)	194 (74.0%)	26 (86.7%)
First not elevated, second elevated	28 (6.1%)	14 (5.3%)	3 (10.0%)
First elevated, second not elevated	32 (6.9%)	25 (9.5%)	1 (3.3%)
Next 3 consecutive PSAs following an elevated PSA***
All 3 not elevated	50 (17.5%)	17 (9.5%)	0 (0.0%)
All 3 elevated	165 (57.9%)	117 (65.4%)	8 (88.9%)
Only 1 elevated	35 (12.3%)	33 (18.4%)	1 (11.1%)
Only 2 elevated	35 (12.3%)	12 (6.7%)	0 (0.0%)

^*Number of elevated PSAs [participants] with at least one subsequent PSA required to be included in analysis was 744 [368], 353 [124], and 68 [40] for the no biopsy, one or more prior biopsy and prostate cancer groups respectively.

^**Number of elevated PSAs [participants] with at least two subsequent PSAs required to be included in analysis was 462 [246], 262 [106], and 30 [22] for the respective groups.

^***Number of elevated PSAs [participants] with at least three subsequent PSAs required to be included in analysis was 285 [168], 179 [82], and 9 [7] for the respective groups.